Cameron Turtle

Dr. Cameron Turtle studies how immune T cells can be engineered to fight hematologic malignancies. His laboratory in the Clinical Research Division at Fred Hutch has extensive expertise in the genetic modification and analysis of T cells, and he leads several investigator-initiated clinical trials of CD19-targeted chimeric antigen receptor (CAR)-modified T-cell therapies for patients with B-cell malignancies. By studying the reasons for success and failure of T cell therapies in patients treated on their clinical trials, the team takes a rational approach to improving treatment of patients with cancer.